COPD pm2.5 drug medicine

Product Description

Chronic obstructive pulmonary disease (COPD) could even be a typical airway disorder. Especially, acute exacerbations of COPD (AECOPD) can significantly reduce pulmonary function. The bulk of AECOPD episodes are attributed to infections, although environmental stress also plays a task. Increasing today's urbanization and associated pollution, especially in developing countries, are shown to contribute to COPD pathogenesis. Elevated levels of particulate (PM) in polluted air are strongly correlated with the onset and development of various respiratory diseases. Reducing COPD PM2.5 levels could even be a viable approach to lower AECOPD incidence, attenuate COPD progression and reduce the associated healthcare burden.

Sparsha Pharma International Pvt. Ltd. was established in 2008 as the first transdermal company in India to engage in R&D, manufacturing and marketing of transdermal products for global markets. We offer COPD pm2.5 drug medicine by introducing patches and we are the India's first Who Certified transdermal patches company.